佛慈制药(002644) - 2025 Q3 - 季度财报

Revenue and Profit - The company's revenue for Q3 2025 was CNY 194,689,733.90, representing a decrease of 7.14% compared to the same period last year[5] - Total operating revenue for Q3 2025 was CNY 624,055,200.70, a decrease of 11.93% compared to CNY 708,531,496.45 in the same period last year[19] - Net profit attributable to shareholders increased by 167.92% to CNY 7,977,760.05, while the year-to-date net profit decreased by 2.54% to CNY 38,082,371.36[5] - Net profit for Q3 2025 was CNY 37,144,761.73, a decline of 8.99% compared to CNY 40,448,681.79 in Q3 2024[20] - The basic earnings per share for the current period was CNY 0.0156, up 168.97% year-on-year[5] - The company reported a basic and diluted earnings per share (EPS) of 0.0746 CNY, slightly down from 0.0765 CNY in the previous period[21] Cash Flow and Financial Activities - Cash flow from operating activities showed a significant increase of 677.92%, reaching CNY 93,505,221.89[12] - The net cash flow from operating activities was 93,505,221.89 CNY, a significant improvement compared to the previous period's negative cash flow of -16,179,550.59 CNY[21] - Total cash inflow from operating activities reached 615,352,024.64 CNY, up from 556,915,313.50 CNY in the prior period, indicating a growth of approximately 10.5%[21] - The net cash flow from investing activities was -17,798,690.52 CNY, worsening from -8,778,238.96 CNY in the prior period[22] - Cash flow from financing activities showed a net outflow of -23,933,988.62 CNY, an improvement from -29,460,365.54 CNY in the previous period[22] - The company received 14,000,000.00 CNY from borrowings, an increase from 10,000,000.00 CNY in the prior period[22] - The company paid 30,124,520.00 CNY in debt repayments, up from 23,400,000.00 CNY in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,523,957,908.79, an increase of 2.19% from the end of the previous year[5] - The company's total assets increased to CNY 2,523,957,908.79 in Q3 2025 from CNY 2,469,785,308.07 in Q3 2024, reflecting a growth of 2.20%[18] - Total liabilities rose to CNY 678,012,772.88 in Q3 2025, compared to CNY 654,805,874.66 in Q3 2024, marking an increase of 3.54%[18] - Deferred income tax assets increased to CNY 65,761,494.90 from CNY 61,809,926.77, showing a growth of 6.36%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,288[13] - The largest shareholder, Lanzhou Foci Pharmaceutical Industry Development Group Co., Ltd., holds 61.63% of the shares, totaling 314,713,676 shares[13] - There are no significant changes in the top 10 shareholders' participation in margin trading[13] - The company remains unaware of any relationships among other shareholders beyond the known connections[13] Operating Costs and Expenses - Total operating costs for Q3 2025 were CNY 564,312,051.85, down 13.39% from CNY 651,587,799.98 year-over-year[19] - Research and development expenses for Q3 2025 were CNY 18,073,933.17, down 17.00% from CNY 21,768,633.09 in the previous year[19] - The company reported a decrease in sales expenses to CNY 72,223,250.25, down 22.36% from CNY 93,057,848.76 year-over-year[19] Other Financial Metrics - The company recorded a significant increase in other income, with operating income rising by 1202.37% to CNY 429,246.10 due to received compensation for penalties[11] - Financial expenses decreased by 40.20% to CNY -2,607,224.19, attributed to increased interest expenses from loans and reduced interest income from bank deposits[11] - The company has not reported any other non-recurring profit and loss items beyond those specified[6] - The company has no preferred shareholders as indicated in the report[15] - The company's long-term equity investments decreased to ¥50,048,818.67 from ¥55,663,345.27, a decline of about 10.9%[16] - Fixed assets decreased to ¥987,758,000.40 from ¥1,028,543,483.45, reflecting a reduction of approximately 4.0%[16] - The total current assets amounted to ¥1,322,828,440.81, up from ¥1,221,884,081.46, indicating a growth of approximately 8.3%[16] Audit Information - The company did not undergo an audit for the third quarter financial report[23]